肠溶阿司匹林治疗冠心病诱发上消化道出血的危险因素及护理对策  

Risk Factors and Nursing Countermeasures of Upper Gastrointestinal Bleeding Induced by Enteric-coated Aspirin in the Treatment of Coronary Heart Disease

作　　者：朱琳 叶发民 ZHU Lin;YE Famin(Coronary Intensive Care Unit,Fuwai China Cardiovascular Hospital,Zhengzhou 450000,Henan,China)

机构地区：[1]阜外华中心血管病医院冠心病重症监护室,河南郑州450000

出　　处：《中国药物滥用防治杂志》2025年第1期35-37,共3页Chinese Journal of Drug Abuse Prevention and Treatment

基　　金：二〇二三年度河南省医学科技攻关计划项目(编号:LHGJ20230130)。

摘　　要：目的:探究肠溶阿司匹林治疗冠心病诱发上消化道出血的危险因素及护理对策。方法:选取我院2022年5月—2023年5月收治的86例肠溶阿司匹林治疗的冠心病患者作为研究对象,依据是否发生上消化道出血将患者分为出血组、未出血组。采用单因素及多因素Logistic回归分析上消化道出血的危险因素。结果:86例患者中发生上消化道出血18例(20.93%)。出血组与非出血组年龄、服药剂量、服药时间、消化道病史、吸烟史、胃黏膜保护剂比较,差异有统计学意义(P<0.05)。多因素Logistic回归分析显示,年龄大、用药剂量是300 mg、服药时间≥3个月、伴消化道病史、未服用胃黏膜保护剂是肠溶阿司匹林治疗冠心病患者发生上消化道出血的危险因素(P<0.05)。结论:肠溶阿司匹林治疗冠心病患者发生上消化道出血的危险因素包括年龄大、用药剂量是300mg、服药时间≥3个月、伴消化道病史、未服用胃黏膜保护剂。针对肠溶阿司匹林治疗冠心病患者可应用PALBI下分级护理,以期降低上消化道出血率,促进患者治疗。Objective:To explore the risk factors and nursing countermeasures of upper gastrointestinal bleeding induced by enteric-coated aspirin in the treatment of coronary heart disease.Methods:Eighty-six patients with coronary heart disease treated with enteric-coated aspirin in our hospital from May 2022 to May 2023 were selected as the research objects.According to whether upper gastrointestinal bleeding occurred,the patients were divided into bleeding group and non-bleeding group.Univariate and multivariate Logistic regression analysis were used to analyze the risk factors of upper gastrointestinal bleeding.Results:There were 18 cases(20.93%)of upper gastrointestinal bleeding in 86 patients.There were significant difference in age,dosage,time of taking medicine,history of digestive tract,history of smoking and gastric mucosal protective agent between the bleeding group and the non-bleeding group(P<0.05).Multivariate Logistic regression analysis showed that older age,dosage of 300 mg,medication time≥3 months,history of digestive tract,and absence of gastric mucosal protective agent were risk factors for upper gastrointestinal bleeding in patients with coronary heart disease treated with enteric-coated aspirin(P<0.05).Conclusion:The risk factors for upper gastrointestinal bleeding in patients with coronary heart disease treated with enteric-coated aspirin include age,dosage of 300 mg,medication time≥3 months,history of digestive tract,and failure to take gastric mucosal protective agent.For patients with coronary heart disease treated with enteric-coated aspirin,PALBI grading nursing can be applied to reduce the rate of upper gastrointestinal bleeding and promote the treatment of patients.

关 键 词：肠溶阿司匹林 冠心病 上消化道出血 危险因素 PALBI下分级护理 

分 类 号：R473.5[医药卫生—护理学]